Xie O - Search Results

1

Biologics in the treatment of active Psoriatic arthritis in China: a network meta-analysis and cost-effectiveness analysis.

Xie O, Wu M, Li A, Meng K, Xiang H, Tan C, Peng L, Ge Y, Wan X. Xie O, et al. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan 9:1-9. doi: 10.1080/14737167.2025.2451740. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2025. PMID: 39783044

2

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study.

Wu M, Ma J, Wang X, Li S, Tan C, Xie O, Li A, Lim AG, Wan X. Wu M, et al. Among authors: xie o. Clin Mol Hepatol. 2024 Dec 3. doi: 10.3350/cmh.2024.0664. Online ahead of print. Clin Mol Hepatol. 2024. PMID: 39623958 Free article.

3

Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.

Meng K, Xiang H, Wu M, Xie O, Li A, Tan C, Wan X. Meng K, et al. Among authors: xie o. Front Pharmacol. 2024 Nov 5;15:1382342. doi: 10.3389/fphar.2024.1382342. eCollection 2024. Front Pharmacol. 2024. PMID: 39564123 Free PMC article.

4

Benchmarking reveals superiority of deep learning variant callers on bacterial nanopore sequence data.

Hall MB, Wick RR, Judd LM, Nguyen AN, Steinig EJ, Xie O, Davies M, Seemann T, Stinear TP, Coin L. Hall MB, et al. Among authors: xie o. Elife. 2024 Oct 10;13:RP98300. doi: 10.7554/eLife.98300. Elife. 2024. PMID: 39388235 Free PMC article.

5

Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.

Li A, Wu M, Xie O, Xiang H, Meng K, Tan C, Wang L, Wan X. Li A, et al. Among authors: xie o. Front Immunol. 2024 Sep 9;15:1464092. doi: 10.3389/fimmu.2024.1464092. eCollection 2024. Front Immunol. 2024. PMID: 39315111 Free PMC article.

6

Effects and Costs of Hepatitis C Virus Elimination for the Whole Population in China: A Modelling Study.

Wu M, Ma J, Li S, Qin S, Tan C, Xie O, Li A, Lim AG, Wan X. Wu M, et al. Among authors: xie o. Pharmacoeconomics. 2024 Dec;42(12):1345-1357. doi: 10.1007/s40273-024-01424-5. Epub 2024 Sep 2. Pharmacoeconomics. 2024. PMID: 39222272

7

Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma.

Wang S, Xie O, Wu M, Xiang H, Tan C, Wan X. Wang S, et al. Among authors: xie o. Expert Rev Pharmacoecon Outcomes Res. 2024 Sep 1:1-6. doi: 10.1080/14737167.2024.2399246. Online ahead of print. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 39215475

8

[Protective effects of 2-methoxyestradiol against hypoxic pulmonary hypertension in neonatal rats].

Xie O, Li SS, Luo Y, Wang L. Xie O, et al. Zhongguo Dang Dai Er Ke Za Zhi. 2024 Jul 15;26(7):757-764. doi: 10.7499/j.issn.1008-8830.2401078. Zhongguo Dang Dai Er Ke Za Zhi. 2024. PMID: 39014954 Free PMC article. Chinese.

9

Streptococcus dysgalactiae subsp. equisimilis infection and its intersection with Streptococcus pyogenes.

Xie O, Davies MR, Tong SYC. Xie O, et al. Clin Microbiol Rev. 2024 Sep 12;37(3):e0017523. doi: 10.1128/cmr.00175-23. Epub 2024 Jun 10. Clin Microbiol Rev. 2024. PMID: 38856686 Review.

10

Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors.

Zhong YY, Anton A, Xie O, Tan N, O'Haire S, Maleki S, Inderjeeth AJ, Parente P, Spain L, Gibbs P, Tran B. Zhong YY, et al. Among authors: xie o. JCO Oncol Pract. 2024 Sep;20(9):1231-1242. doi: 10.1200/OP.24.00036. Epub 2024 May 28. JCO Oncol Pract. 2024. PMID: 38805663

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters